NDUFAF1
ENSG00000137806
Target class
Enzyme
Chromosome
15
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFAF1
- Gene name
- NADH:ubiquinone oxidoreductase complex assembly factor 1
- Gene symbol
- NDUFAF1
- Protein name
- Complex I intermediate-associated protein 30, mitochondrial (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 1)
- CIA30
- CGI-65
- Gene biotype
- Protein coding
- Gene family
- Mitochondrial respiratory chain complex assembly factors|Mitochondrial complex I assembly complex
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 40.45
- Tissue specificity (Gini)
- 0.154
- Tissue specificity (tau)
- 0.54
- KEGG gene identifiers
- hsa:51103
- Reactome pathways
- R-HSA-6799198
- Protein interaction confidence
- 0.959065
- Protein interaction partners
- 62
- End position
- 41409403
- Start position
- 41387218
- Chromosome
- 15
- Strand
- Reverse
- Mitochondrion . Mitochondrion matrix . Note=Peripherally associated with the matrix face of the mitochondrial inner membrane. .
- Mitochondria
- PubMed 16218961
- PubMed 17557076
- Tissue specificity (tau)
- 0.539637
- Expression inequality (Gini)
- 0.153723
Expression in transcripts per million
- Testis
- 40.45
- Adrenal Gland
- 37.67
- Cells - Cultured fibroblasts
- 34.52
- Muscle - Skeletal
- 33.8
- Cells - EBV-transformed lymphocytes
- 28.32
Expression in transcripts per million
- Testis40.45
- Adrenal Gland37.67
- Cells - Cultured fibroblasts34.52
- Muscle - Skeletal33.8
- Cells - EBV-transformed lymphocytes28.32
- Brain - Frontal Cortex (BA9)25.32
- Heart - Left Ventricle22.76
- Brain - Cerebellar Hemisphere22.57
- Nerve - Tibial21.9
- Brain - Spinal cord (cervical c-1)21.53
- Cervix - Ectocervix21.03
- Ovary20.2
- Brain - Cortex19.98
- Thyroid19.95
- Cervix - Endocervix19.77
- Brain - Cerebellum19.44
- Fallopian Tube19.13
- Uterus19.09
- Pituitary19.01
- Brain - Hypothalamus18.82
- Esophagus - Muscularis18.79
- Kidney - Medulla18.76
- Brain - Anterior cingulate cortex (BA24)18.5
- Colon - Sigmoid18.49
- Artery - Coronary18.32
And 29 more, listed on the interactive page.
Biological processes
- GO:0032981
- GO:0005739
- GO:0005743
- GO:0160295
Molecular functions
- GO:0005515
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor